Stay updated on Glesatinib Combo With Nivolumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Glesatinib Combo With Nivolumab in NSCLC Clinical Trial page.

Latest updates to the Glesatinib Combo With Nivolumab in NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe ClinicalTrials.gov page’s displayed site revision changes from v3.8.0 to v3.8.1; the study record content remains unchanged.SummaryDifference0.0%

- Check10 days agoChange DetectedThe ClinicalTrials.gov record for this Phase 2 lung cancer study is available, with details about its design, participating locations, results, and study documents. It states that the study was terminated due to sponsor portfolio reprioritization and is no longer recruiting.SummaryDifference64%

- Check17 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check31 days agoChange DetectedA notice was added about NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence,” and the site revision changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check45 days agoChange DetectedThe footer revision identifier was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the study record with a standard error page. The additions reflect the 403 message, basic HTML boilerplate, and a Home link in the header/footer.SummaryDifference19%

Stay in the know with updates to Glesatinib Combo With Nivolumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Glesatinib Combo With Nivolumab in NSCLC Clinical Trial page.